BDH Industries Past Earnings Performance
Past criteria checks 3/6
BDH Industries has been growing earnings at an average annual rate of 12.4%, while the Pharmaceuticals industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 9.6% per year. BDH Industries's return on equity is 15.9%, and it has net margins of 11.3%.
Key information
12.4%
Earnings growth rate
12.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 9.6% |
| Return on equity | 15.9% |
| Net Margin | 11.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BDH Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 874 | 99 | 74 | 0 |
| 31 Dec 23 | 814 | 88 | 73 | 0 |
| 30 Sep 23 | 726 | 79 | 72 | 0 |
| 30 Jun 23 | 755 | 83 | 70 | 0 |
| 31 Mar 23 | 745 | 82 | 70 | 0 |
| 31 Dec 22 | 707 | 82 | 69 | 0 |
| 30 Sep 22 | 779 | 85 | 69 | 0 |
| 30 Jun 22 | 726 | 76 | 68 | 0 |
| 31 Mar 22 | 694 | 72 | 66 | 0 |
| 31 Dec 21 | 707 | 72 | 66 | 0 |
| 30 Sep 21 | 630 | 64 | 66 | 0 |
| 30 Jun 21 | 615 | 63 | 65 | 0 |
| 31 Mar 21 | 575 | 64 | 63 | 0 |
| 31 Dec 20 | 496 | 57 | 66 | 0 |
| 30 Sep 20 | 519 | 56 | 67 | 0 |
| 30 Jun 20 | 497 | 50 | 69 | 0 |
| 31 Mar 20 | 595 | 59 | 75 | 0 |
| 31 Dec 19 | 551 | 53 | 71 | 0 |
| 30 Sep 19 | 604 | 59 | 71 | 0 |
| 30 Jun 19 | 585 | 57 | 70 | 0 |
| 31 Mar 19 | 517 | 48 | 68 | 0 |
| 31 Dec 18 | 551 | 55 | 68 | 0 |
| 30 Sep 18 | 473 | 48 | 67 | 0 |
| 30 Jun 18 | 470 | 46 | 65 | 0 |
| 31 Mar 18 | 410 | 38 | 63 | 0 |
| 31 Dec 17 | 387 | 32 | 63 | 0 |
| 30 Sep 17 | 390 | 29 | 61 | 0 |
| 30 Jun 17 | 376 | 28 | 60 | 0 |
| 31 Mar 17 | 437 | 33 | 58 | 0 |
| 31 Dec 16 | 435 | 34 | 54 | 0 |
| 30 Sep 16 | 412 | 31 | 52 | 0 |
| 30 Jun 16 | 470 | 33 | 51 | 0 |
| 31 Mar 16 | 461 | 32 | 51 | 0 |
| 31 Dec 15 | 493 | 32 | 97 | 2 |
| 30 Sep 15 | 481 | 29 | 96 | 2 |
| 30 Jun 15 | 445 | 27 | 50 | 0 |
| 31 Mar 15 | 446 | 26 | 49 | 0 |
| 31 Dec 14 | 453 | 27 | 94 | 1 |
| 30 Sep 14 | 480 | 28 | 93 | 1 |
| 30 Jun 14 | 452 | 26 | 44 | 0 |
| 31 Mar 14 | 426 | 23 | 91 | 1 |
| 31 Dec 13 | 416 | 21 | 78 | 2 |
| 30 Sep 13 | 428 | 21 | 76 | 2 |
| 30 Jun 13 | 429 | 19 | 37 | 0 |
Quality Earnings: 524828 has a high level of non-cash earnings.
Growing Profit Margin: 524828's current net profit margins (11.3%) are higher than last year (11%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524828's earnings have grown by 12.4% per year over the past 5 years.
Accelerating Growth: 524828's earnings growth over the past year (20.3%) exceeds its 5-year average (12.4% per year).
Earnings vs Industry: 524828 earnings growth over the past year (20.3%) did not outperform the Pharmaceuticals industry 24.4%.
Return on Equity
High ROE: 524828's Return on Equity (15.9%) is considered low.